Valuation: Captor Therapeutics Spolka Akcyjna

Market Cap 343M 87.08M 78.11M 71.38M 65.16M 123M 8.19B 127M 860M 4.37B 327M 320M 13.79B P/E 2026 *
-10.4x
P/E 2027 * -12.7x
Enterprise Value 281M 71.26M 63.91M 58.41M 53.32M 100M 6.7B 104M 704M 3.57B 267M 262M 11.28B EV / Sales 2026 *
6.29x
EV / Sales 2027 * 14.6x
Free-Float
70.73%
Yield 2026 *
-
Yield 2027 * -
1 week+3.77%
Current month+3.77%
1 month-17.91%
3 months-21.43%
6 months-28.85%
Current year-23.61%
1 week 49
Extreme 49
56
1 month 49
Extreme 49
66.7
Current year 49
Extreme 49
89.2
1 year 44.1
Extreme 44.1
89.2
3 years 31.2
Extreme 31.2
109.5
5 years 31.2
Extreme 31.2
193.98
10 years 31.2
Extreme 31.2
209
Manager TitleAgeSince
Chief Executive Officer 41 30/05/2025
Director of Finance/CFO - 31/01/2025
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Chairman 54 29/06/2022
Director/Board Member 74 29/06/2022
Director/Board Member - 29/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
26/02/26 Buy 1,100 0.0198%
12/12/25 Free

Chairman

360,074 6.5128%
12/12/25 Don

Chairman

360,074 6.5128%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.77%+22.22%-44.67% 87.08M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.02%+2.63%+46.49%+162.92% 40.68B
Weighted average by Cap. +0.65%+3.07%+49.90%+165.83%

Financials

2026 *2027 *
Net sales 44.6M 11.32M 10.15M 9.28M 8.47M 15.96M 1.06B 16.46M 112M 568M 42.49M 41.58M 1.79B 21.5M 5.46M 4.89M 4.47M 4.08M 7.69M 513M 7.94M 53.92M 274M 20.48M 20.04M 864M
Net income -12.23M -3.11M -2.79M -2.55M -2.32M -4.38M -292M -4.52M -30.68M -156M -11.66M -11.41M -492M -27.3M -6.93M -6.22M -5.68M -5.18M -9.77M -651M -10.08M -68.46M -348M -26.01M -25.45M -1.1B
Net Debt -62.33M -15.82M -14.19M -12.97M -11.84M -22.31M -1.49B -23.01M -156M -794M -59.39M -58.11M -2.51B -30M -7.61M -6.83M -6.24M -5.7M -10.74M -716M -11.07M -75.24M -382M -28.58M -27.97M -1.21B
Projected Income Statement - Annual - Captor Therapeutics Spolka Akcyjna
Logo Captor Therapeutics Spolka Akcyjna
Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
Employees
-
Date Price Change Volume
06/11/26 PLN 54.00 -1.82% 2,599
05/11/26 PLN 55.00 +8.27% 11,835
04/11/26 PLN 50.80 +1.40% 4,479
03/11/26 PLN 50.10 -1.76% 5,547
02/11/26 PLN 51.00 -3.77% 5,354
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Captor Therapeutics Spolka Akcyjna
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
54.00PLN
Average target price
91.90PLN
Spread / Average Target
+70.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Captor Therapeutics Spolka Akcyjna